PDX Pharma has met all the milestones of the phase I portion of our fast-track SBIR project “Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer” and has been approved for starting the phase II portion of the project by the NCI. The project period is from 06/01/2018 to 05/31/2020.
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, is currently serving as the guest editor in the special issue “Nanoparticles in Therapeutic Applications” for the MDPI Bioengineering journal. The special issue focuses on nanoparticle development and applications in broad ranges of diseases and delivery routes.
More information can be found here.
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, has served as a reviewer for the ZRG1 IMST-L (55) PAR-17-240 ‘Innovative Research in Cancer Nanotechnology (IRCN)’ (R01) Study Section for the National Institute of Health (NIH), held in Washington DC on March 29, 2018.
PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, has developed PDX-001 as a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer. The work has been funded by fast-track phase I/II SBIR awards from the NIH/NCI as well as angel funds (the Prospect Creek Foundation […]
PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ and triple-negative breast cancer. The development is a collaborative work between PDX Pharma and the Biomedical Engineering Department of OHSU. The work has been funded by fast-track phase I/II SBIR awards from NIH/NCI, a phase I SBIR award from NIH/NCATS, and angel […]
PDX Pharmaceuticals, LLC has been selected to participate as a member of the 2017-2018 Cohort of the NIH SBIR/STTR Commercialization Accelerator Program (CAP) for Phase II awardees. “NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in […]
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on September 14, 2017.
PDX Pharma welcomes a new Research Assistant, Daniel Bejan. Daniel’s recently graduated from WSU Vancouver with a Major in Biology and Minors in Chemistry and Molecular Biology (GPA 3.94). He is our top pick among 120 applicants. We are excited to add him to our team.
Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I SBIR grant from the National Center for Advancing Translational Sciences to support our pre-clinical research activity during the period of Aug 2017 – Aug 2018. The grant is entitled “Development of topical formulation of […]
PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.